Gene and Cell Therapy – Multimedia

Whether your key vector strategy is based on adenoviruses (AV), adeno-associated viruses (AAV) or lentiviruses (LV), the development of these genetic analysis tools is enabling researchers to develop safer gene therapies – with greater speed.

In this infographic, we explore the latest advances in gene therapy, including production and delivery mechanisms.

Speaking at the Advances in Drug Discovery & Development 2022 online symposium, Leonardo Ferreira discusses how engineering human regulatory T cells can protect against an immune attack in type 1 diabetes.

Greater appreciation for the complex and dynamic connections between metabolic poise and immune cell function enables researchers to monitor and control how metabolic reprogramming

Download this eBook to discover new analytical solutions to accelerate AAV-based gene therapy.

In this video, Oxford Biomedica, an innovative global gene and cell therapy company with operations in the UK and US, describes the automation of an assay requiring a 10-day cell-based workflow

RNA-based therapies can modulate cells in a controlled and targeted manner, effectively acting as gene therapies. But, as with any therapeutic, RNA therapeutics must undergo strict quality control (QC) to ensure the product is exactly as specified, with no errors or alternate products.

This tech note highlights technology that switches easily between DNA and RNA analysis to ensure quick and reliable quality checks and precise sizing of DNA and IVT RNA products.

The cell therapy manufacturing process requires the guidance of chemical manufacturing and controls for analytical method development focusing on the critical quality attributes (CQAs).

Gene therapy aims to be a one-time treatment targeting a faulty gene that causes a disease and either replacing it with a functional gene or altering the gene expression.